相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response
Laura Valerio et al.
ENDOCRINE-RELATED CANCER (2020)
State-of-the-Art Strategies for Targeting RET-Dependent Cancers
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
Benjamin J. Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Advances in Targeting RET-Dependent Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2020)
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
Dora Dias-Santagata et al.
THYROID (2020)
RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
Massimo Santoro et al.
GENES (2020)
Genetic Alterations in Pediatric Thyroid Cancer Using a Comprehensive Childhood Cancer Gene Panel
Ali S. Alzahrani et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
Michael C. Kreissl et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
RET,NTRK,ALK,BRAF, andMETFusions in a Large Cohort of Pediatric Papillary Thyroid Carcinomas
Barbora Pekova et al.
THYROID (2020)
Selpercatinib Aimed at RET-Altered Cancers
Razelle Kurzrock
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family
Julie Guilmette et al.
HUMAN PATHOLOGY (2019)
Long-term outcome after DNA-based prophylactic neck surgery in children at risk of hereditary medullary thyroid cancer
Andreas Machens et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib
Simon S. Terzyan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.
Patrick Schoffski et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors Is Intraductal Correct?
Alena Skalova et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions
Cristina R. Antonescu et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations
Thereasa A. Rich et al.
CLINICAL CANCER RESEARCH (2019)
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations
Rossella Elisei et al.
GENES (2019)
506PTPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
A Drilon et al.
ANNALS OF ONCOLOGY (2019)
The Pfam protein families database in 2019
Sara El-Gebali et al.
NUCLEIC ACIDS RESEARCH (2019)
GDNF and the RET Receptor in Cancer: New Insights and Therapeutic Potential
Lois M. Mulligan
FRONTIERS IN PHYSIOLOGY (2019)
Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study
Frederic Castinetti et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing
Raffaele Ciampi et al.
ISCIENCE (2019)
BOS172738: A novel highly potent and selective RET kinase inhibitor in Phase 1 clinical development
Mitchell Keegan et al.
CANCER RESEARCH (2019)
Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors
Samuel A. Wells
ENDOCRINE-RELATED CANCER (2018)
A comprehensive review on MEN2B
Frederic Castinetti et al.
ENDOCRINE-RELATED CANCER (2018)
Structure and function of RET in multiple endocrine neoplasia type 2
Ivan Plaza-Menacho
ENDOCRINE-RELATED CANCER (2018)
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Alexander Drilon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
F. Pietrantonio et al.
ANNALS OF ONCOLOGY (2018)
Selective RET kinase inhibition for patients with RET-altered cancers
V. Subbiah et al.
ANNALS OF ONCOLOGY (2018)
Drug resistance profiles of mutations in the RET kinase domain
Xuan Liu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Novel targeted therapeutics for MEN2
Sara Redaelli et al.
ENDOCRINE-RELATED CANCER (2018)
65 YEARS OF THE DOUBLE HELIX Exploiting insights on the RET receptor for personalized cancer medicine
Lois M. Mulligan
ENDOCRINE-RELATED CANCER (2018)
A secondary RET mutation in the activation loop conferring resistance to vandetanib
Takashi Nakaoku et al.
NATURE COMMUNICATIONS (2018)
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2018)
Incidence and prevalence of sporadic and hereditary MTC in Denmark 1960-2014: a nationwide study
Jes Sloth Mathiesen et al.
ENDOCRINE CONNECTIONS (2018)
The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases
Vicky W. W. Tsai et al.
CELL METABOLISM (2018)
RET rearrangements are actionable alterations in breast cancer
Bhavna S. Paratala et al.
NATURE COMMUNICATIONS (2018)
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study
Alain Ravaud et al.
EUROPEAN JOURNAL OF CANCER (2017)
Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma
Gilbert J. Cote et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
Maria E. Cabanillas et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial
Marcia S. Brose et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand
Linda Yang et al.
NATURE MEDICINE (2017)
Targeting Obesity and Cachexia: Identification of the GFRAL Receptor-MIC-1/GDF15 Pathway
Samuel N. Breit et al.
TRENDS IN MOLECULAR MEDICINE (2017)
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer
Valentina De Falco et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma
M. Schlumberger et al.
ANNALS OF ONCOLOGY (2017)
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Martin Schlumberger et al.
CLINICAL CANCER RESEARCH (2016)
RET mutation and increased angiogenesis in medullary thyroid carcinomas
Antonella Verrienti et al.
ENDOCRINE-RELATED CANCER (2016)
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Inigo Lancia et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma
Qingling Huang et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma
Andreas M. Heilmann et al.
ONCOLOGY (2016)
RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements
Ivan Plaza-Menacho et al.
CELL REPORTS (2016)
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology
Brendan Frett et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
RAS proto-oncogene in medullary thyroid carcinoma
Margarida M. Moura et al.
ENDOCRINE-RELATED CANCER (2015)
RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma
Elizabeth G. Grubbs et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort
Cecile N. Chougnet et al.
THYROID (2015)
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
Samuel A. Wells et al.
THYROID (2015)
Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
Zheng Zhao et al.
ACS CHEMICAL BIOLOGY (2014)
Treatment of Advanced Thyroid Cancer With Axitinib: Phase 2 Study With Pharmacokinetic/Pharmacodynamic and Quality-of-Life Assessments
Laura D. Locati et al.
CANCER (2014)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal et al.
CELL (2014)
A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H
Keith C. Bible et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma
Tatsuji Mizukami et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In trans
Ivan Plaza-Menacho et al.
MOLECULAR CELL (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function
Diogo Fonseca-Pereira et al.
NATURE (2014)
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
Thomas Wiesner et al.
NATURE COMMUNICATIONS (2014)
RET Recognition of GDNF-GFRaα1 Ligand by a Composite Binding Site Promotes Membrane-Proximal Self-Association
Kerry M. Goodman et al.
CELL REPORTS (2014)
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
Kiyoshi Okamoto et al.
CANCER LETTERS (2013)
Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: Report of a case and a literature review of tandem RET mutations with in silico analysis
Kanako-Tanase Nakao et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2013)
Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update
Samuel A. Wells et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS
Nishant Agrawal et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers
Julio C. Ricarte-Filho et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase
Luca Mologni et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Structure and Physiology of the RET Receptor Tyrosine Kinase
Carlos F. Ibanez
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Somatic RAS Mutations Occur in a Large Proportion of Sporadic RET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified Exon
A. Boichard et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation
P. Ballerini et al.
LEUKEMIA (2012)
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Doron Lipson et al.
NATURE MEDICINE (2012)
KIF5B-RET fusions in lung adenocarcinoma
Takashi Kohno et al.
NATURE MEDICINE (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
Low Prevalence of the Somatic M918T RET Mutation in Micro-Medullary Thyroid Cancer
Cristina Romei et al.
THYROID (2012)
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)
C. Romei et al.
CLINICAL ENDOCRINOLOGY (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Role of H2O2 in RET/PTC1 Chromosomal Rearrangement Produced by Ionizing Radiation in Human Thyroid Cells
Rabii Ameziane-El-Hassani et al.
CANCER RESEARCH (2010)
c-Ret-mediated hearing loss in mice with Hirschsprung disease
Nobutaka Ohgami et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474
Francesca Carlomagno et al.
ENDOCRINE-RELATED CANCER (2009)
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Richard T. Kloos et al.
THYROID (2009)
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
Junji Matsui et al.
CLINICAL CANCER RESEARCH (2008)
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer:: A 10-year follow-up study
Rossella Elisei et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
New therapeutic approaches to treat medullary thyroid carcinoma
Martin Schlumberger et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2008)
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Hirschsprung disease, associated syndromes and genetics: a review
J. Amiel et al.
JOURNAL OF MEDICAL GENETICS (2008)
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting
Ivan Plaza-Menacho et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells
Nagako Akeno-Stuart et al.
CANCER RESEARCH (2007)
Enteric nervous system development and Hirschsprung's disease: advances in genetic and stem cell studies
Tiffany A. Heanue et al.
NATURE REVIEWS NEUROSCIENCE (2007)
The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth
Carmen Canibano et al.
EMBO JOURNAL (2007)
Tyrosine kinase receptor RET is a key regulator of Peyer's Patch organogenesis
Henrique Veiga-Fernandes et al.
NATURE (2007)
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis
Roy S. Herbst et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia
Taranjit S. Gujral et al.
CANCER RESEARCH (2006)
Structure and chemical inhibition of the RET tyrosine kinase domain
Phillip P. Knowles et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B
Aaron N. Cranston et al.
CANCER RESEARCH (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Ablation of persephin receptor glial cell line-derived neurotrophic factor family receptor α4 impairs thyroid calcitonin production in young mice
PH Lindfors et al.
ENDOCRINOLOGY (2006)
Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to γ-radiation:: A model of carcinogenic chromosomal rearrangement induced by ionizing radiation
CM Caudill et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors
F Carlomagno et al.
ONCOGENE (2004)
The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease
MC Bordeaux et al.
EMBO JOURNAL (2000)
Regulation of cell fate decision of undifferentiated spermatogonia by GDNF
XJ Meng et al.
SCIENCE (2000)
分享论文
